Clinical trialUNITERAREApr 5
Researchers are testing a new cancer treatment that takes a patient's own immune cells, modifies them in a lab to recognize and attack their specific cancer, and then puts them back into the body. This Phase 1 trial is for people with blood cancers like leukemia and lymphoma. The treatment is personalized—each patient's cells are customized based on their individual cancer's unique mutations.
WHY IT MATTERSThis trial offers patients with hematologic malignancies access to a cutting-edge personalized immunotherapy that targets their cancer's unique mutations, potentially offering a new treatment option for those who may have limited alternatives.
Clinical trialUNITERAREApr 3
Researchers are testing a new experimental drug called KST-6051 in patients with advanced solid tumors (cancers that form in organs or tissues) that have a specific genetic mutation called KRAS. This is an early-stage study (Phase 1) that will test different doses of the drug to find the safest and most effective amount. The trial is now accepting patients and is expected to start in April 2026.
WHY IT MATTERSThis trial offers patients with KRAS-mutated solid tumors access to a novel targeted therapy before it becomes widely available, potentially providing a treatment option for cancers that are often difficult to treat.
Clinical trialUNITERAREApr 3
Researchers are testing a new experimental drug called EPI-326 in people with two types of cancer: non-small cell lung cancer and head and neck cancer, both caused by mutations in the EGFR gene. This is an early-stage study (Phase 1) to see if the drug is safe and how much patients can tolerate. The study is currently accepting new participants and is expected to start in April 2026.
WHY IT MATTERSThis trial offers access to a novel EGFR-targeted therapy for patients with EGFR-mutant lung or head and neck cancers who may have limited treatment options or resistance to current therapies.
Clinical trialUNITERAREApr 3
Researchers are testing a new drug called Xaluritamig to treat Ewing sarcoma, a rare bone cancer that has come back or stopped responding to previous treatments. This is an early-stage study (Phase 1) that will include children, teenagers, and adults. The study is now accepting patients and is expected to start in April 2026.
WHY IT MATTERSThis trial offers a potential new treatment option for patients with relapsed or refractory Ewing sarcoma, a rare pediatric cancer with limited treatment alternatives after standard therapies fail.
Clinical trialUNITERAREApr 3
Researchers are testing a new combination treatment for advanced kidney cancer that has spread to other parts of the body. The treatment combines two immunotherapy drugs (nivolumab and ipilimumab) with an experimental live biotherapeutic product called EXL01. This Phase 1 trial is now accepting patients to see if adding EXL01 to the standard immunotherapy improves outcomes.
WHY IT MATTERSThis trial offers metastatic renal cell carcinoma patients access to a novel combination approach that may enhance the effectiveness of existing immunotherapies by incorporating a live biotherapeutic product.
Clinical trialUNITERAREApr 3
Prelude Therapeutics is testing a new drug called PRT12396 in people with certain blood cancers called myeloproliferative neoplasms. This is an early-stage study (Phase 1) to see if the drug is safe and how it works in the body. The study is now accepting patients and is expected to start in April 2026.
WHY IT MATTERSThis trial offers access to a potentially new treatment option for patients with myeloproliferative neoplasms who may have limited alternatives, particularly if they have specific subtypes targeted by this drug.
Clinical trialUNITERAREApr 3
Researchers are testing a new type of cell therapy made from umbilical cord blood to treat T-cell lymphoma that has stopped responding to other treatments. The therapy uses special immune cells called NK cells that are engineered to recognize and attack cancer cells. This is an early-stage study (Phase 1) that is now accepting patients.
WHY IT MATTERSThis trial offers a potential new treatment option for patients with relapsed or refractory T-cell lymphoma who have limited alternatives after standard therapies fail, with enrollment beginning in April 2026.